Defence Therapeutics Inc.
DTCFF
$0.44
$0.000.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -89.81% | -14.72% | 15.02% | 32.65% | 90.60% |
| Total Depreciation and Amortization | -47.24% | -9.23% | -60.85% | -26.35% | 149.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.67% | 4.21% | 61.25% | 245.88% | -95.63% |
| Change in Net Operating Assets | 38.76% | -144.01% | -88.34% | -592.14% | -113.88% |
| Cash from Operations | -110.30% | -916.22% | -53.02% | -99.27% | 53.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -67.67% | -- | -187.10% | 100.00% | -- |
| Total Debt Issued | -- | 13,233.33% | -100.00% | -- | -- |
| Total Debt Repaid | 100.00% | 45.68% | 57.69% | -188.46% | -1,976.81% |
| Issuance of Common Stock | -96.53% | -- | -100.00% | 190.59% | 88.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.20% | -- | -- | -98.56% | 40.72% |
| Cash from Financing | -95.79% | 14,194.68% | -117.70% | 181.15% | 59.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -196,960.00% | 1,344.79% | -82.97% | 1,019.62% | 99.93% |